Evidence map›Paper›PMID 39758200›Full record

ArticleFrontiers in public health2024

Financial assessment and diagnosis of abnormal data of listed companies in public health and wellness industry.

Xiao Liu, Yanhong Li, Shengnan Zhang

Abstract read
In one paragraph

Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xiao LiuCollege of Finance and Economics, Wan Jiang University of Technology, Maanshan, China.
Yanhong LiCollege of Finance and Economics, Wan Jiang University of Technology, Maanshan, China.
Shengnan ZhangCollege of Finance and Economics, Wan Jiang University of Technology, Maanshan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, the present status of the public health and wellness sector in China is examined. The main objective is to evaluate the financial risk among publicly listed companies in the sector. Despite the significant expansion of the industry, research in this domain remains limited. Moreover, it frequently lacks depth, especially when it comes to financial studies designed especially for publicly traded companies. Current models for assessing corporate financial risk are frequently applied in diverse industries without necessary adjustments. Therefore, this study examines the financial performance and operational health of five publicly listed anonymized companies between 2020 and 2023. Using an efficient methodology that includes reliable data collection and quality assurance, we analyze key performance indicators such as annual revenues, liquidity ratios, and debt-to-equity ratios to assess financial stability and growth potential. Our findings reveal varied revenue trends shaped by external market shocks such as the COVID-19 pandemic. These trends highlight both the resilience of the sector and its vulnerabilities. To evaluate potential financial risks and outliers, the abnormal revenue patterns are also identified using Z-score. Benchmarking is also conducted using industry averages which provides a clearer understanding of competitive positioning. Several suggestions are made in light of the analysis to manage debt, increase liquidity, and leverage digital transformation for long-term growth. Several future directions are also presented to continue research in the domain. Overall, this study offers valuable information for stakeholders navigating the complexities of the public health and wellness industry in China.

Indexed as

COVID-19Public HealthChinaHealth PromotionHumansIndustrySARS-CoV-2abnormal data diagnosisfinancial risk assessmenthealth and safetypublic healthwellness industry

Identifiers

PMID39758200
PMCPMC11695276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.